Published in:
01-02-2018 | Brief Report
Cardioprotection by minocycline in a rabbit model of ischemia/reperfusion injury: Detection of cell death by in vivo 111In-GSAO SPECT
Authors:
Takayoshi Yamaki, MD, PhD, Hans J. de Haas, MD, Nobuhiro Tahara, MD, PhD, Artiom Petrov, PhD, Dilbahar Mohar, MD, Nezam Haider, PhD, Jun Zhou, MD, Atsuko Tahara, MD, Yasuchika Takeishi, MD, PhD, Hendrikus H. Boersma, PharmD, PhD, Tiziano Scarabelli, MD, PhD, Annapoorna Kini, MD, MRCP, H. William Strauss, MD, Jagat Narula, MD, PhD
Published in:
Journal of Nuclear Cardiology
|
Issue 1/2018
Login to get access
Abstract
Background
Preclinical studies indicate that minocycline protects against myocardial ischemia/reperfusion injury. In these studies, minocycline was administered before ischemia, which can rarely occur in clinical practice. The current study aimed to evaluate cardioprotection by minocycline treatment upon reperfusion.
Methods
Rabbits were subjected to myocardial ischemia/reperfusion injury and received either intravenous minocycline (n = 8) or saline (n = 8) upon reperfusion. Cardiac cell death was assessed by in vivo micro-SPECT/CT after injection of Indium-111-labeled 4-(N-(S-glutathionylacetyl)amino) phenylarsonous acid (111In-GSAO). Thereafter, hearts were explanted for ex vivo imaging, γ-counting, and histopathological characterization.
Results
Myocardial damage was visualized by micro-SPECT/CT imaging. Quantitative GSAO uptake (expressed as percent injected dose per gram, %ID/g) in the area at risk was lower in minocycline-treated animals than that in saline-treated control animals (0.32 ± 0.13% vs 0.48 ± 0.15%, P = 0.04). TUNEL staining confirmed the reduction of cell death in minocycline-treated animals.
Conclusions
This study demonstrates cardioprotection by minocycline in a clinically translatable protocol.